No Data
No Data
With 55% Institutional Ownership, OmniAb, Inc. (NASDAQ:OABI) Is a Favorite Amongst the Big Guns
Institutional Investors May Adopt Severe Steps After OmniAb, Inc.'s (NASDAQ:OABI) Latest 13% Drop Adds to a Year Losses
OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates
Benchmark Co. Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $8
A Quick Look at Today's Ratings for OmniAb(OABI.US), With a Forecast Between $8 to $11
No Data